Nitazoxanide
- Generic Name
- Nitazoxanide
- Brand Names
- Alinia, Busulfex
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9N3O5S
- CAS Number
- 55981-09-4
- Unique Ingredient Identifier
- SOA12P041N
- Background
Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .
- Indication
用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。
- Associated Conditions
- Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
- Associated Therapies
- -
Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
- Conditions
- Chronic Hepatitis c
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 100
- Registration Number
- NCT01276756
- Locations
- 🇪🇬
Cairo University, Cairo, Egypt
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 624
- Registration Number
- NCT01227421
- Locations
- 🇺🇸
Health Sciences Research Center, Elmira, New York, United States
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- National Liver Institute, Egypt
- Target Recruit Count
- 200
- Registration Number
- NCT01197157
- Locations
- 🇪🇬
National Liver Institute, Shebin El-Kom, Menoufiya, Egypt
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
- Conditions
- Minimal Hepatic EncephalopathyHepatic Cirrhosis
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Target Recruit Count
- 60
- Registration Number
- NCT01135628
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 8
- Registration Number
- NCT01074203
- Locations
- 🇺🇸
Mayo Clinic College of Medicine, Rochester, Minnesota, United States
Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 79
- Registration Number
- NCT01056380
- Locations
- 🇺🇸
Health Sciences Research Center at Asthma and Allergy Associates, P.C., Elmira, New York, United States
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
- Conditions
- HIV InfectionHepatitis C Infection
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 68
- Registration Number
- NCT00991289
- Locations
- 🇺🇸
Stanford AIDS Clinical Trials Unit CRS, Palo Alto, California, United States
🇺🇸Columbia P&S CRS, New York, New York, United States
🇺🇸Trillium Health ACTG CRS, Rochester, New York, United States
4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: NitazoxanideBiological: Peginterferon alfa-2a
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2008-10-01
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 40
- Registration Number
- NCT00763568
- Locations
- 🇪🇬
Digestive Disease Center, Tanta, Egypt
Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus
- Conditions
- DiarrheaRotavirus Infection
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2008-05-26
- Lead Sponsor
- Centro Pediatrico Albina de Patino
- Target Recruit Count
- 75
- Registration Number
- NCT00683982
- Locations
- 🇧🇴
Centro Pediatrico Albina Patiño, Cochabamba, Bolivia
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 112
- Registration Number
- NCT00637923
- Locations
- 🇺🇸
Florida Center for Gastroenterology, Largo, Florida, United States
🇺🇸New York Presbyterian-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Palo Alto VA Healthcare System, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.